Drug intelligence / Profile preview

IR-783

Development stage
Preclinical
Modality
Small Molecules, Nanoparticles → Drug Delivery Systems
Administration
Intravenous, Intratumoral
01

Overview

IR-783 is a heptamethine cyanine near-infrared (NIR) fluorescent dye primarily used as a probe for in vivo imaging of tumor cells. It exhibits excitation/emission maxima around 776/798 nm and is valued for its ability to selectively accumulate in tumor tissues due to enhanced permeability and retention effects. Beyond imaging applications, recent studies indicate that IR-783 can significantly inhibit tumor growth and induce apoptosis when used alone or in combination with other agents. It has also been formulated into liposomes for photodynamic therapy (PDT), showing efficacy against advanced cancers such as tongue and breast cancer. Additionally, it serves as a starting material for the synthesis of related NIR dyes like IR808[1][4][6][7].

Other names
2-[2-[2-Chloro-3-[2-[1,3-dihydro-3,3-dimethyl-1-(4-sulfobutyl)-2H-indol-2-ylidene]-ethylidene]-1-cyclohexen-1-yl]-ethenyl]-3,3-dimethyl-1-(4-sulfobutyl)-3H-indolium hydroxide inner salt sodium salt

Beyond the preview

Go deeper on IR-783.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IR-783.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call